Loading stock data…
$6.87-0.72 (-9.49%)
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need.
Eupraxia Pharmaceuticals Inc. in the Healthcare sector is trading at $6.87 with a market capitalization of $556M. Wall Street consensus targets $16.61 (9 analysts), implying a +141.8% move over the next 12 months. The stock is currently 26% below its 52-week high of $9.32, remaining 6.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$18.10M↓ | -$15.96M↑ | -$16.16M↓ | -$6.88M↑ | -$8.26M |
| Net Income | -$14.49M↓ | -$12.65M↑ | -$16.71M↓ | -$6.36M↑ | -$8.74M |
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with s...